SCHEMBL3010909

SCHEMBL3010909

CCc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccccc4Br)CC3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.61
MAPK1 P28482 5/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
SMN1; SMN2 Q16637 7/20 0.58
MAPT P10636 6/20 0.58
ALDH1A1 P00352 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.53
GBA1 P04062 2/20 0.45
RAB9A P51151 3/20 0.44
HSD17B10 Q99714 2/20 0.44
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
NPSR1 Q6W5P4 2/20 0.43
NPC1 O15118 2/20 0.43
AR P10275 1/20 0.43
TP53 P04637 1/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003210 0.92 LMNA (0.59) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3002208 0.89 LMNA (0.62) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3011596 0.89 SMN1; SMN2 (0.61) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3019990 0.88 LMNA (0.67) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3009126 0.87 LMNA (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3012669 0.87 MAPT (0.61) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008092 0.87 SMN1; SMN2 (0.76) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3015062 0.86 MAPT (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3007256 0.86 LMNA (0.45) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3008167 0.85 KMT2A (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.